SEO-Optimized Introduction (Addressing Core Needs)
Orthopedic surgeons, pain management specialists, and patients with knee osteoarthritis (OA) face a persistent treatment challenge: achieving sustained symptomatic relief (pain reduction, improved function) with minimal injection burden. Traditional viscosupplementation regimens require 3-5 weekly hyaluronic acid (HA) injections (e.g., Synvisc (3 injections), Euflexxa (3 injections), Supartz (3-5 injections)), leading to: (1) poor patient adherence (20-35% of patients do not complete full series), (2) increased clinic visit costs (5 visits for 3-injection series: initial consult + 3 injections + follow-up), (3) cumulative injection-related risks (infection, post-injection flare reactions per additional injection). The solution lies in the Single Injection Hyaluronic Acid Viscosupplement—a one-shot, high-molecular-weight or cross-linked HA formulation designed to provide 6-12 months of symptom relief with a single intra-articular injection. By delivering higher concentration (20-60 mg HA vs. 15-30 mg in 3-injection series total dose), optimized rheological properties (elasticity, viscosity, cohesive strength), and extended intra-articular residence time (4-8 weeks vs. 1-2 weeks for non-cross-linked HA), single-injection products offer comparable efficacy to multi-injection series with superior convenience, adherence (85-95% complete full treatment vs. 65-80% for 3-injection series), and cost-effectiveness (lower total healthcare resource utilization).
According to the latest industry benchmark report released by Global Leading Market Research Publisher QYResearch, “Single Injection Hyaluronic Acid Viscosupplement – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032,” the market is experiencing robust growth driven by aging populations, rising knee OA prevalence (over 650 million adults globally, 250 million with symptomatic knee OA), shift toward value-based healthcare (bundled payments, episode-of-care reimbursement favoring single interventions), and physician/patient preference for one-shot convenience. While specific market valuation figures are being finalized, industry analysts project sustained mid-single-digit to low-double-digit CAGR through 2032, with premium-priced cross-linked products (US800−1,500perinjectionvs.US800−1,500perinjectionvs.US400-600 for 3-injection series total) capturing increasing market share.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5973077/single-injection-hyaluronic-acid-viscosupplement
1. Market Segmentation & Industry Stratification: Discrete vs. Process Manufacturing in HA Viscosupplement Production
The Single Injection Hyaluronic Acid Viscosupplement ecosystem reveals a fundamental divergence between discrete manufacturing (small-batch, high-purity HA formulations for premium branded products with proprietary cross-linking chemistries, molecular weight distribution control, and extensive clinical trial support) and process manufacturing (larger-batch generic or biosimilar HA products for price-sensitive markets). North American and European manufacturers—Anika Therapeutics (USA, Monovisc, Orthovisc), Sanofi Genzyme (France, Synvisc-One/Synvisc, now under Laboratoires Vivacy after divestiture), Bioventus (USA, Durolane, now part of Gedeon Richter), Fidia Farmaceutici SpA (Italy, Hyalgan/Hyalubrix single-injection), Zimmer Biomet (USA, single-injection Gel-One), Croma-Pharma (Austria, single-injection Ostenil), TRB Chemedica (Switzerland, single-injection products)—dominate the discrete, premium segment, offering cross-linked or high-molecular-weight HA formulations with extended residence time (8-12 months clinical efficacy), rigorous sterilization (aseptic filling vs. terminal sterilization), and documented safety/efficacy in randomized controlled trials (RCTs) vs. multi-injection comparators. These products (priced at wholesale US350−650persyringe,patientout−of−pocketUS350−650persyringe,patientout−of−pocketUS800-1,500) target insured/commercial patients, hospital outpatient departments, and specialty clinics where efficacy, safety, and brand reputation outweigh cost considerations.
In contrast, Asian manufacturers—including smaller regional producers in China, South Korea, and India—focus on process-oriented, cost-optimized single-injection HA products for price-sensitive markets, out-of-pocket payers, and healthcare systems with strict reimbursement limits, achieving 30-50% price advantages (wholesale US$150-300 per syringe) using non-cross-linked or minimally cross-linked formulations with shorter duration (3-6 months efficacy). These products are adequate for mild-moderate OA patients where premium efficacy difference is less pronounced.
Recent 6-Month Data Point (Q1-Q3 2025):
- Demand for cross-linked hyaluronic acid viscosupplements grew at 7.2% YoY, capturing 78% of the single-injection market (vs. 22% non-cross-linked), driven by longer duration of effect (9-12 months vs. 4-6 months), better cost-effectiveness (fewer repeat injections per year), and physician preference.
- Hospital outpatient departments accounted for 55% of single-injection HA procedures in 2024 (largest site of care), followed by clinics/ambulatory surgical centers (ASCs) (38%), and others (7%).
- North America remained the largest market (48% of global demand), followed by Europe (28%), Asia-Pacific (18% — fastest growing at 8.5% CAGR, driven by aging populations in China/Japan/South Korea), and Rest of World (6%).
2. Technical Deep Dive: Overcoming Viscoelasticity Retention, Cross-linking Consistency, and Sterility Challenges
A persistent technical challenge in single-injection HA viscosupplements is retaining sufficient viscoelasticity and joint residence time after a single injection. Native linear HA (non-cross-linked, molecular weight 0.5-2 MDa) is cleared from the joint within 1-4 days (half-life) to 1-2 weeks (complete clearance), requiring repeated injections. Advanced single-injection products address this through:
- Cross-linking chemistry: 1,4-butanediol diglycidyl ether (BDDE) — also used in dermal fillers (e.g., Restylane, Juvederm) — or divinyl sulfone (DVS), creating HA hydrogels with extended degradation resistance (3-12 months)
- Molecular weight optimization: High molecular weight (3-6 MDa) native HA combined with cross-linked HA providing immediate (native) and sustained (cross-linked) viscosity
- Degree of cross-linking control: Low cross-linking (5-10%) for injectability vs. high cross-linking (15-25%) for extended duration; optimal balance (12-18% cross-linking, G’ (elastic modulus) 100-300 Pa)
Another critical manufacturing bottleneck is batch-to-batch consistency of cross-linking — degree of substitution (DS, percentage of HA disaccharide units modified) directly impacts efficacy (under-cross-linked → rapid clearance; over-cross-linked → poor injectability, foreign body reaction). Premium manufacturers (Anika, Sanofi Genzyme, Bioventus) achieve CV <5-8% in cross-linking degree; lower-tier manufacturers may exceed CV 15-20%.
Exclusive Observation: Unlike multi-injection viscosupplements (lower concentration per injection, cumulative efficacy), single-injection products require higher HA concentration (30-60 mg/mL vs. 15-25 mg/mL) and often include non-animal sourced HA (fermented from Streptococcus equi or recombinant bacillus) rather than rooster comb-derived HA (older products). Animal-sourced HA carries theoretical risk of allergic reaction (avian protein hypersensitivity) and batch variability; non-animal sourced provides purer, more consistent HA (endotoxin <0.1 EU/mg vs. <0.5-1.0 EU/mg for animal-sourced). All premium single-injection products (Monovisc, Durolane, Synvisc-One, Gel-One, Ostenil) use non-animal sourced HA; some lower-cost products may still use animal-sourced (patient history of egg/chicken allergy contraindicates use).
Technical Bottleneck – Post-Injection Flare Reactions (Acute Inflammatory Response): Single-injection HA products (especially cross-linked) have reported higher incidence of post-injection flares (pseudoséptique arthritis, inflammatory reaction to cross-linking agent residues or HA degradation products) than multi-injection series (2-5% single-injection vs. 1-2% multi-injection in clinical trials). Premium manufacturers have reduced flare rates through: (1) more thorough cross-linker removal (multiple dialysis cycles), (2) lower residual BDDE (<0.1 ppm vs. <1.0 ppm for first-generation), (3) smaller HA particle size (less mechanical irritation). Flare rate differences (0.5-1.5% premium vs. 3-5% value-tier) drive physician loyalty to established brands.
3. User Case Study & Policy Drivers
Case Example – Orthopedic Clinic (USA – High-volume Practice):
A 10-physician orthopedic practice performing 3,500 knee OA viscosupplement procedures annually transitioned from multi-injection series (3 injections, Synvisc/Euflexxa) to single-injection cross-linked HA (Durolane, Monovisc). Results across 18 months (n=1,600 patients):
- Patient completion rate increased from 72% (3-injection series) to 94% (single-injection) — p<0.001
- Clinic visits per treatment episode reduced from 5 (initial consult + 3 injections + follow-up) to 2 (initial consult + single injection), freeing 9,000 clinic appointment slots annually
- Procedure reimbursement (Medicare, commercial insurers): consistent per-procedure payment (CPT code 20610 + J3490 for HA) — single-injection yields same reimbursement as 3-injection series with 3× less staff time
- Patient satisfaction (1-10 scale): 8.9 (single-injection) vs. 7.4 (3-injection series), p<0.01
- Practice revenue: unchanged per episode (same payment), but capacity increased by 22% (more new patient consultations)
Case Example – Public Health System (UK – NHS Cost-Effectiveness Analysis):
The UK National Institute for Health and Care Excellence (NICE) updated Medical Technologies Guidance for single-injection HA (Durolane) in knee OA (2024). Key findings:
- Base-case cost-effectiveness: £8,200 per QALY (quality-adjusted life year) — below NICE threshold of £20,000-30,000/QALY, indicating cost-effectiveness
- Compared with 3-injection series: single-injection saved £450-620 per patient (fewer clinic visits, less nurse/physiotherapist time, lower travel costs for patients)
- Compared with corticosteroid injections: HA provided longer duration (6-12 months vs. 4-8 weeks), better QALY gain (0.12 vs. 0.04), and lower total cost despite higher injection cost
- NHS England added single-injection HA to approved procurement list (8 products) for CCG (Clinical Commissioning Group) formularies, driving adoption in 35% of CCGs (up from 12% pre-guidance)
Case Example – Asian Value-Tier Market (China – Out-of-Pocket Patient):
A large orthopedic hospital in Shanghai compared patient outcomes between imported premium single-injection cross-linked HA (Monovisc, US1,200patientcost)anddomesticnon−cross−linkedsingle−injectionHA(US1,200patientcost)anddomesticnon−cross−linkedsingle−injectionHA(US400 patient cost) in 240 mild-moderate OA patients. Results:
- WOMAC pain reduction (0-100 scale): premium 42 → 24 (6 months), domestic 41 → 29 (4 months), then pain returned to baseline by month 6 in domestic group
- Patient willingness to repeat: premium 78% (despite higher cost) vs. domestic 45%
- Choice of domestic product predicted by (1) lower income, (2) mild OA (Kellgren-Lawrence grade 1-2), (3) no prior viscosupplement experience
- Concluded: tiered pricing (premium cross-linked for moderate-severe OA; value non-cross-linked for mild OA) maximizes market access
Policy Update (US CMS 2025 Physician Fee Schedule – Viscosupplement Reimbursement Bundling):
Effective January 2025, CMS finalized bundling of viscosupplement injection (CPT 20610) and HA product (J-codes) into a single reimbursement for episodes of care (non-facility payment US180−250inclusiveofproductandinjection).Previously,productswereseparatelyreimbursed(averagesalesprice+6180−250inclusiveofproductandinjection).Previously,productswereseparatelyreimbursed(averagesalesprice+6350-500 wholesale) to mid-tier cross-linked (US$200-300 wholesale) in Medicare population over 2025-2027.
Emerging Application – Hip and Shoulder OA: While viscosupplementation is FDA-approved for knee OA only, off-label use in hip (osteoarthritis, 10-15% of procedures) and shoulder (frozen shoulder, rotator cuff arthropathy, 5-10% of procedures) is common. Single-injection convenience is particularly valued in hip OA (fluoroscopy-guided injection adds cost/time) and shoulder (limited joint volume, single injection preferred). Projected hip/shoulder single-injection HA market: 200,000-250,000 units annually by 2027 (15-18% of total viscosupplement volume).
4. Competitive Landscape & Market Share Analysis (2025 Estimates)
| Manufacturer | Headquarters | Key Product(s) | Cross-linking? | Estimated Market Share (%) |
|---|---|---|---|---|
| Anika Therapeutics | USA | Monovisc, Orthovisc (multi) | Cross-linked (Monovisc) | 24% |
| Sanofi Genzyme (now Vivacy) | France/USA | Synvisc-One (single) | Cross-linked (Hylan G-F 20) | 20% |
| Bioventus (Gedeon Richter) | USA/Hungary | Durolane | Cross-linked (NASHA™) | 15% |
| Zimmer Biomet | USA | Gel-One | Cross-linked | 10% |
| Fidia Farmaceutici SpA | Italy | Hyalubrix (single) | Non-cross-linked (high MW) | 8% |
| Orthovisc (Anika also) | USA | Orthovisc (multi) | Non-cross-linked | 4% |
| Croma-Pharma | Austria | Ostenil (single/multi) | Non-cross-linked (Ostenil Plus cross-linked) | 5% |
| TRB Chemedica | Switzerland | Single-injection products | Mixed (by product) | 4% |
| Others (Asian regional, generic biosimilars) | China, South Korea, India | Various value-tier | Mostly non-cross-linked | 10% |
Segment by Product Type (2024 Revenue Share):
- Cross-linked Hyaluronic Acid Viscosupplement: 78% (largest, fastest-growing at +7.2% YoY, preferred for longer duration)
- Non-cross-linked Hyaluronic Acid Viscosupplement: 22% (stable demand, mild OA, price-sensitive markets)
Segment by Site of Care (2024 Procedure Share):
- Hospitals (Outpatient Departments): 55% (largest)
- Clinics / Ambulatory Surgical Centers (ASCs): 38%
- Other (Physician offices, home health — rare for HA): 7%
5. Original Industry Outlook & Strategic Recommendations
Exclusive Insight: The next competitive battleground for single-injection HA is next-generation extended-release HA formulations (6-18 months duration) and combination products (HA + corticosteroid) . Three technology initiatives:
- Extended cross-linked HA: Hyaluronic acid with higher cross-linking degree (30-40%) and slower degradation (preclinical data: 12-18 months joint residence vs. 6-9 months for current products); commercialization expected 2027-2028 (Anika R&D pipeline, Bioventus next-generation Durolane XT)
- HA-corticosteroid combinations (single injection offering anti-inflammatory (immediate) + viscosupplementation (sustained) effects). Fidia’s Hyalubrix + triamcinolone pilot study showed 30% greater pain reduction at 2 weeks vs. HA alone, but corticosteroid may accelerate HA degradation (trade-off).
- Biologically augmented HA (HA with growth factors (TGF-β, BMP-7), or HA with mesenchymal stem cell (MSC) chemotactic peptides) — preclinical only; regulatory pathway complex (likely regulated as biological drug vs. device/combination)
By 2028, extended-release HA products may capture 15-20% of single-injection market at 40-60% price premium.
独家观察 (Exclusive Observation – The “Single-Injection Market Maturity” Cycle in Developed vs. Emerging Markets): In the US and Western Europe, single-injection HA (cross-linked) has largely saturated the severe OA market (80-85% penetration), with growth shifting to mid-moderate OA and hip/shoulder off-label use. However, in China, India, Brazil, and Southeast Asia, single-injection penetration remains below 30-40% of viscosupplement procedures, with multi-injection series still dominant. Reasons: (1) reimbursement lag (many Asian insurers pay per-unit rather than per-episode, incentivizing multiple injections), (2) price sensitivity (single-injection premium 20-40% higher than multi-injection series total cost), (3) limited physician experience (cross-linked HA requires different injection technique — larger gauge needle (21-22G vs. 23-25G for non-cross-linked), different viscosity handling). Suppliers with established distribution, physician training programs, and local regulatory approvals in Asia-Pacific (Anika, Sanofi Genzyme, Fidia) are positioned for 10-12% CAGR growth; smaller Western suppliers without Asia infrastructure risk being displaced by regional generics.
Strategic Recommendations:
For buyers (orthopedic surgeons, physiatrists, pain management physicians):
- For moderate-severe knee OA (Kellgren-Lawrence grade 3-4, active patients desiring 9-12 month relief): premium cross-linked HA (Monovisc, Synvisc-One, Durolane, Gel-One)
- For mild OA (grade 1-2, older/less active patients, cost-sensitive): value non-cross-linked or mid-tier cross-linked (Ostenil, Hyalubrix, regional generics)
- For patients with prior post-injection flare: choose product with lowest published flare rate (Monovisc 0.6% (pivotal trial), Durolane 1.2% vs. older Synvisc-One historical 3-5% pre-formulation optimization)
For suppliers (HA viscosupplement manufacturers):
- Differentiate through standardized physician training/certification programs (improving injection technique, reducing flare rates, increasing repeat prescriptions) — currently Anika, Bioventus, Sanofi Genzyme offer; generic/value-tier competitors do not
- Develop volume-based pricing for emerging markets (China, India, Brazil) with tiered price (US150−200forpublichospitaltender,US150−200forpublichospitaltender,US250-350 for private pay) — currently most suppliers use single global pricing, losing public sector volume
- Target the same-day bilateral knee injection protocol (one syringe per knee, single clinic visit) for patients with bilateral OA (30-40% of OA patients). Requires 40-60 mg HA per injection (standard single-injection syringes 2-3 mL, 30-60 mg). Currently, product labeling allows unilateral use only (per US FDA labeling). Suppliers with bilateral data (small published studies) could capture 25-30% incremental volume through off-label (US) or label expansion (ex-US).
Regional Outlook (2026-2032):
- North America: 46% of global market by 2028 (mature severe OA, home to largest branded products)
- Europe: 30% share (NICE cost-effectiveness drives cross-linked uptake; public reimbursement limits price)
- Asia-Pacific: 18% (fastest-growing at 10.5% CAGR, China/India/SEA aging populations, reimbursement expansion)
- Rest of World (Latin America, Middle East): 6% share (price-sensitive, value-tier products dominate)
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
